SB-236057-A: A Selective 5-HT1B Receptor Inverse Agonist

Claire Roberts, Jeanette Watson, Gary W. Price, Derek N. Middlemiss
{"title":"SB-236057-A: A Selective 5-HT1B Receptor Inverse Agonist","authors":"Claire Roberts,&nbsp;Jeanette Watson,&nbsp;Gary W. Price,&nbsp;Derek N. Middlemiss","doi":"10.1111/j.1527-3458.2001.tb00209.x","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>5-HT<sub>1B</sub> autoreceptors are involved in the control of extracellular 5-HT levels from both the terminal and cell body regions of serotonergic neurons. In this manuscript we review the pharmacological and pharmacokinetic data available for the selective and potent 5-HT<sub>1B</sub> receptor inverse agonist, SB-236057-A (1′-ethyl-5-(2′-methyl-4′-(5-methyl-1,3,4-oxadiazolyl-2-yl)biphenyl-4-carbonyl)-2,3,6,7-tetrahydrospiro (furo[2,3-f]indole-3,4′-piperidine) hydrochloride). SB 236057-A has been shown to have high affinity for human 5-HT<sub>1B</sub> receptors (p<i>K</i><sub>i</sub>= 8.2) and displays 80 or more fold selectivity for the human 5-HT<sub>1B</sub> receptor over other 5-HT receptors and a range of additional receptors, ion channels and enzymes. In functional studies at human 5-HT<sub>1B</sub> receptors SB-236057-A displayed inverse agonism (pA<sub>2</sub>= 8.9) using [<sup>35</sup>S]GTPγS binding, and silent antagonism (pA<sub>2</sub>= 9.2) using cAMP accumulation. SB-236057-A also acted as an antagonist at the 5-HT terminal autoreceptor as measured by [<sup>3</sup>H]5-HT release from electrically stimulated guinea pig and human cortical slices.</p>\n <p>In the guinea pig, pharmacokinetic analysis demonstrated that SB-236057-A was bioavailable and according to <i>in vivo</i> pharmacodynamic assays it enters brain and has a long duration of action. Importantly no side effect liability was evident at relevant doses from anxiogenic, cardiovascular, sedative or migraine viewpoints.</p>\n <p> <i>In vivo</i> microdialysis studies demonstrated that SB-236057-A is an antagonist in the guinea pig cortex but has no effect on extracellular 5-HT levels <i>per se.</i> In contrast, SB-236057-A increased extracellular 5-HT levels in the guinea pig dentate gyrus. This increase in 5-HT release was comparable to that observed after 14 days of paroxetine administration.</p>\n <p>SB-236057-A has been a useful tool in confirming that, in either guinea pigs or humans, the terminal 5-HT autoreceptor is of the 5-HT<sub>1B</sub> subtype. It appears that acute 5-HT<sub>1B</sub> receptor blockade, by virtue of increased 5-HT release in the dentate gyrus, may provide a rapidly acting antidepressant.</p>\n </div>","PeriodicalId":94307,"journal":{"name":"CNS drug reviews","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2006-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1527-3458.2001.tb00209.x","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS drug reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2001.tb00209.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17

Abstract

5-HT1B autoreceptors are involved in the control of extracellular 5-HT levels from both the terminal and cell body regions of serotonergic neurons. In this manuscript we review the pharmacological and pharmacokinetic data available for the selective and potent 5-HT1B receptor inverse agonist, SB-236057-A (1′-ethyl-5-(2′-methyl-4′-(5-methyl-1,3,4-oxadiazolyl-2-yl)biphenyl-4-carbonyl)-2,3,6,7-tetrahydrospiro (furo[2,3-f]indole-3,4′-piperidine) hydrochloride). SB 236057-A has been shown to have high affinity for human 5-HT1B receptors (pKi= 8.2) and displays 80 or more fold selectivity for the human 5-HT1B receptor over other 5-HT receptors and a range of additional receptors, ion channels and enzymes. In functional studies at human 5-HT1B receptors SB-236057-A displayed inverse agonism (pA2= 8.9) using [35S]GTPγS binding, and silent antagonism (pA2= 9.2) using cAMP accumulation. SB-236057-A also acted as an antagonist at the 5-HT terminal autoreceptor as measured by [3H]5-HT release from electrically stimulated guinea pig and human cortical slices.

In the guinea pig, pharmacokinetic analysis demonstrated that SB-236057-A was bioavailable and according to in vivo pharmacodynamic assays it enters brain and has a long duration of action. Importantly no side effect liability was evident at relevant doses from anxiogenic, cardiovascular, sedative or migraine viewpoints.

In vivo microdialysis studies demonstrated that SB-236057-A is an antagonist in the guinea pig cortex but has no effect on extracellular 5-HT levels per se. In contrast, SB-236057-A increased extracellular 5-HT levels in the guinea pig dentate gyrus. This increase in 5-HT release was comparable to that observed after 14 days of paroxetine administration.

SB-236057-A has been a useful tool in confirming that, in either guinea pigs or humans, the terminal 5-HT autoreceptor is of the 5-HT1B subtype. It appears that acute 5-HT1B receptor blockade, by virtue of increased 5-HT release in the dentate gyrus, may provide a rapidly acting antidepressant.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
SB-236057-A:一种选择性5-HT1B受体反向激动剂
5-HT1B自身受体参与控制5-羟色胺能神经元的末端和细胞体区域的细胞外5-HT水平。在本文中,我们综述了选择性和强效5-HT1B受体反向激动剂SB-236057-A(1′-乙基-5-(2′-甲基-4′-(5-甲基-1,3,4-恶二唑基-2-基)联苯-4-羰基)-2,3,6,7-四氢螺环(呋[2,3-f]吲哚-3,4′-哌啶)盐酸盐)的药理学和药代动力学数据。SB 236057-A已被证明对人5-HT1B受体具有高亲和力(pKi=8.2),并且对人5-HT 1B受体显示出比其他5-HT受体和一系列附加受体、离子通道和酶高80倍或更多的选择性。在对人5-HT1B受体的功能研究中,SB-236057-A使用[35S]GTPγS结合表现出反向激动作用(pA2=8.9),使用cAMP积累表现出沉默拮抗作用(pA2=9.2)。SB-236057-A也作为5-HT末端自身受体的拮抗剂,通过从电刺激的豚鼠和人皮层切片释放[3H]5-HT来测量。在豚鼠中,药代动力学分析表明SB-236057-A具有生物可利用性,根据体内药效学分析,它进入大脑并具有长时间的作用。重要的是,从焦虑、心血管、镇静剂或偏头痛的角度来看,在相关剂量下没有明显的副作用。体内微透析研究表明,SB-236057-A是豚鼠皮层中的拮抗剂,但对细胞外5-HT水平本身没有影响。相反,SB-236067-A增加了豚鼠齿状回中的细胞外5-HT水平。这种5-HT释放的增加与帕罗西汀给药14天后观察到的增加相当。SB-236057-A是一种有用的工具,用于确认在豚鼠或人类中,末端5-HT自身受体是5-HT1B亚型。急性5-HT1B受体阻断,由于齿状回5-HT释放增加,可能提供一种快速作用的抗抑郁药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
ERRATUM Cortagine: Behavioral and Autonomic Function of the Selective CRF Receptor Subtype 1 Agonist Guanfacine and Guanfacine Extended Release: Treatment for ADHD and Related Disorders Pharmacology of the β-Carboline FG-7142, a Partial Inverse Agonist at the Benzodiazepine Allosteric Site of the GABAA Receptor: Neurochemical, Neurophysiological, and Behavioral Effects AUTHOR INDEX FOR VOLUME 13
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1